Search results
Earnings call: AbbVie surpasses Q1 expectations, announces CEO transition By Investing.com
Investing.com· 4 days agoThe earnings call also marked a significant leadership transition, with CEO Rick Gonzalez announcing...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 13 hours agoPomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE). Such investors are advised to contact Danielle Peyton ...
Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024
Morningstar· 3 days agoCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company ...
Lawmakers honor popular Kansas City DJ following cancer death
KCTV 5 Kansas City· 2 days agoA popular Kansas City radio DJ is gone, but memories of his laughter and spirit live on through a...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Holdings Cut by Russell Investments Group Ltd.
ETF DAILY NEWS· 2 days agoRussell Investments Group Ltd. lowered its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 84.5% during the fourth quarter, according to its most recent Form 13F filing with ...
Earnings call: AbbVie surpasses Q1 expectations, announces CEO transition
Investing.com· 4 days agoThe earnings call also marked a significant leadership transition, with CEO Rick Gonzalez announcing...
Syros Pharmaceuticals (NASDAQ:SYRS) Stock Price Passes Below 50 Day Moving Average of $5.94
ETF DAILY NEWS· 1 day agoSyros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Free Report)’s stock price passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $5.94 ...
Brokerages Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Price Target at $195.08
ETF DAILY NEWS· 2 days agoShares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the ...
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Of Texas/Texas Am I. University Sells...
ETF DAILY NEWS· 1 day agoAileron Therapeutics, Inc. (NASDAQ:ALRN – Get Free Report) major shareholder Of Texas/Texas Am I. University sold 20,315 shares of Aileron Therapeutics stock in a transaction that occurred on ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 3 days agoReplay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies Phase 1/2 study in patients with relapsed/refractory AML